Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987833 | 0.89 | CCR2 (0.47) | KCNH2CACNA1ICCR2P2RX3PTGER4 | |
| SCHEMBL12584097 | 0.86 | MEN1 (0.45) | KCNH2CACNA1ICCR2MEN1KMT2A | |
| SCHEMBL988831 | 0.85 | VCP (0.43) | KCNH2CACNA1ICCR2MEN1KMT2A | |
| SCHEMBL987962 | 0.82 | HCRTR1 (0.40) | DRD2DRD4 | |
| SCHEMBL986580 | 0.82 | DRD2 (0.37) | HTR4DRD2DRD4CNR1 | |
| SCHEMBL987576 | 0.81 | MCL1 (0.38) | KCNH2P2RX3CHRM1ALDH1A1CNR2 | |
| SCHEMBL12584136 | 0.80 | PTGER4 (0.43) | KCNH2CACNA1ICCR2MEN1KMT2A | |
| SCHEMBL12583944 | 0.79 | MEN1 (0.43) | KCNH2CACNA1ICCR2MEN1KMT2A | |
| SCHEMBL988182 | 0.78 | HTR4 (0.35) | PTGER4PTGDRHTR4CHRM1ALDH1A1 | |
| SCHEMBL12585483 | 0.78 | PTGER4 (0.45) | CCR2P2RX3PTGER4PTGDRHTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598355-B2 | Amide compound | ASTELLAS PHARMA INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2565191-A1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | KCNH2 3210/4885CACNA1I 4404/4885CCR2 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.